Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union is a new study that finds Canadian patients are waiting, on average, more than 450 days longer than Americans and Europeans to access new, potentially life-saving drugs. That’s because pharmaceutical companies are reluctant to launch new drugs in Canada because of a number of factors including the smaller market size, weaker intellectual property protections, and the federal government’s strict pricing policies.
